Status:
COMPLETED
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SKI2670
Lead Sponsor:
SK Chemicals Co., Ltd.
Conditions:
Endometriosis
Eligibility:
FEMALE
20+ years
Phase:
PHASE1
Brief Summary
In this Phase I study, the primary objective is to investigate the safety and tolerability of SKI2670 after oral administration in healthy female subjects. And secondary objective is to investigate th...
Detailed Description
In this Phase I study, the primary objective is to investigate the safety and tolerability of SKI2670 after oral administration in healthy female subjects. Secondary objective is to investigate the p...
Eligibility Criteria
Inclusion
- Female, 20 years of age and older
- Weight between 40kg\~70kg
- Women who agreed using double contraception method and spermicide, avoiding breast-feeding for at least 30days after IP(investigational product) dosing
- A history of regular menstrual cycles (cycle: 28±7day, duration: 2\~7day) for at least 2 years and a positive ovulation test between day 11 and 21 in the preceding menstrual cycle of IP(investigational product) dosing
Exclusion
- Women who are pregnant or serum/urine hCG(human chorionic gonadotropin) positive or breast-feeding
- A history of breast cancer, genital cancer or any estrogen dependent tumor
- Specified or unspecified diagnosed infertility or history of natural abortion over three times
- A history of taking other Investigational product within 60days before screening visit or taking ETC drug(Ethical drugs), oriental medicine or OTC drugs(Over-the-Counter drugs) within 14days before screening visit
- Clinically significant Gynecological disease identified by ultrasonography including estrogen dependent tumor or lesion, sever inflammation or synechia
- AST(Aspartate aminotransferase), ALT(Alanine aminotransferase) ≥ 2.5 times the upper limit of normal
- QTc \> 450ms on electrocardiogram result
Key Trial Info
Start Date :
June 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT02202408
Start Date
June 1 2014
End Date
August 1 2016
Last Update
October 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 138-736